{
    "clinical_study": {
        "@rank": "53553", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1 - Urelumab (0.1 mg/kg) + Rituxan (375 mg/m2)", 
                "arm_group_type": "Experimental", 
                "description": "Urelumab (BMS-663513) 0.1 mg/kg intravenous infusion every 3 weeks up to 2 years, depending on response and tolerability to study drug.\nRituxan (Rituximab) 375 mg/m2 intravenous infusion 4 weekly doses every 12 weeks up to 2 years, depending on response and tolerability to study drug"
            }, 
            {
                "arm_group_label": "Arm 2 - Urelumab (0.3 mg/kg) + Rituxan (375 mg/m2)", 
                "arm_group_type": "Experimental", 
                "description": "Urelumab (BMS-663513) 0.3 mg/kg intravenous infusion every 3 weeks up to 2 years, depending on response and tolerability to study drug.\nRituxan (Rituximab) 375 mg/m2 intravenous infusion 4 weekly doses every 12 weeks up to 2 years, depending on response and tolerability to study drug"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine the safety, tolerability and maximum tolerated dose\n      of Urelumab in combination with Rituximab in patients with B-cell Non-Hodgkins Lymphoma or\n      Chronic Lymphocytic Leukemia (CLL)"
        }, 
        "brief_title": "Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "B-Cell Malignancies", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Intervention model: Dose Escalation (part 1) of study= Sequential Design; Dose Expansion\n      (part 2) of study= Parallel Design"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n          -  Clinical diagnosis of relapsed/refractory B-cell Malignancies per International\n             Workshop Group (IWG) 2007 criteria or 2008 International Workshop on CLL (IWCLL)\n             criteria\n\n          -  Progressed or refractory to at least 1 prior line of standard therapy\n\n          -  Subjects in Expansion cohorts are restricted to relapsed/refractory Chronic\n             Lymphocytic Leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) or Follicular\n             Lymphoma (FL) subjects who are refractory to rituximab. Rituximab refractoriness is\n             defined as progression during treatment on prior rituximab therapy or rituximab\n             containing regimen or progression within 6 months from last received dose of\n             rituximab\n\n          -  Follicular Lymphoma (FL) must have at least 1 lesion that can be biopsied at\n             screening and on treatment\n\n          -  Eastern Cooperative Oncology Group (ECOG) of 0 to 1\n\n        Exclusion Criteria:\n\n          -  Active or progressing brain metastases\n\n          -  Other concomitant malignancies (with some exceptions per protocol)\n\n          -  Active or history of autoimmune disease\n\n          -  Positive test for human immunodeficiency virus (HIV) 1&2 or known Acquired immune\n             deficiency syndrome (AIDS)\n\n          -  History of any hepatitis (A, B or C)\n\n          -  History of grade 3-4 drug-related hepatitis\n\n          -  Known current drug or alcohol abuse\n\n          -  Active tuberculosis (TB)\n\n          -  Prior therapy with any antibody/drug that targets the T cell coregulatory proteins,\n             including but not limited to, anti-CD137, Anti Cytotoxic T lymphocyte-associated\n             antigen 4 (anti-CTLA4) or Anti-Glucocorticoid-induced tumor necrosis factor receptor\n             (anti-GITR).  However, Anti-Programmed Death-1 (anti-PD-1), Anti-Programmed\n             Death-Ligand1 (anti-PD-L1) are permissible as prior therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "138", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01775631", 
            "org_study_id": "CA186-017"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1 - Urelumab (0.1 mg/kg) + Rituxan (375 mg/m2)", 
                    "Arm 2 - Urelumab (0.3 mg/kg) + Rituxan (375 mg/m2)"
                ], 
                "intervention_name": "Urelumab", 
                "intervention_type": "Biological", 
                "other_name": "BMS-663513"
            }, 
            {
                "arm_group_label": [
                    "Arm 1 - Urelumab (0.1 mg/kg) + Rituxan (375 mg/m2)", 
                    "Arm 2 - Urelumab (0.3 mg/kg) + Rituxan (375 mg/m2)"
                ], 
                "intervention_name": "Rituxan", 
                "intervention_type": "Biological", 
                "other_name": "Rituximab"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "John Timmerman, Site 0011"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "Ucla"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ronald Levy, Site 0001"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Izidore Lossos, Site 0012"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University Of Miami Sylvester Comprehensive Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0021"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Brian Link, Site 0004"
                }, 
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "University Of Iowa Hospitals And Clinics"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0020"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mark Kaminski, Site 0006"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University Of Michigan Health System"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Martin Gutierrez, Site 0015"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "John Theurer Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrew Zelenetz, Site 0010"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0017"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John Godwin, Site 0002"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97213"
                    }, 
                    "name": "Portland Providence Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0019"
                }, 
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0018"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0009"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlottesvillle", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22908"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and tolerability of Urelumab in combination with Rituximab as measured by incidence of adverse events (AEs), serious AEs, death, vital sign changes, electrocardiograms (ECGs), physical examination results, and laboratory test abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 60 days after last dose of Urelumab"
            }, 
            {
                "measure": "Safety and tolerability of Urelumab in combination with Rituximab as measured by incidence of adverse events (AEs), serious AEs, death, vital sign changes, electrocardiograms (ECGs), physical examination results, and laboratory test abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 110 days after last dose of Rituximab"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01775631"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy-Antitumor Activity of Urelumab in combination with Rituximab as measured by best overall response, progression-free survival, time to response, and duration of response", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 2 years"
            }, 
            {
                "measure": "Maximum observed serum concentration (Cmax) of Urelumab and Rituximab", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 60 of Follow-up"
            }, 
            {
                "measure": "Time of maximum observed serum concentration (Tmax) of Urelumab", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 60 of Follow-up"
            }, 
            {
                "measure": "Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of Urelumab", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 60 of Follow-up"
            }, 
            {
                "measure": "Trough observed serum concentration (Cmin) of Urelumab and Rituximab", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 60 of Follow-up"
            }, 
            {
                "measure": "Area under the concentration-time curve in one dosing interval [AUC(TAU)] of Urelumab", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 60 of Follow-up"
            }, 
            {
                "measure": "Immunogenicity of Urelumab in combination with Rituximab as  determined by blood sample measurements of anti-drug antibodies (ADA)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to approximately 2.33 years"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}